CMMB (Chemomab Therapeutics) NonCurrent Deferred Liabilities: $0.00 Mil (As of Mar. 2026)


CMMB Chemomab Therapeutics Ltd CMMB
33 GF Score
Price $2.40
View Full Analysis

What is Chemomab Therapeutics NonCurrent Deferred Liabilities?

Chemomab Therapeutics CMMB +5.73% 33 NonCurrent Deferred Liabilities is $0.00 Mil as of Mar. 2026. GuruFocus rates CMMB with a GF Score™ of 33/100.

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Chemomab Therapeutics's non-current deferred liabilities for the quarter that ended in Mar. 2026 was $0.00 Mil.

Chemomab Therapeutics NonCurrent Deferred Liabilities Related Terms

Chemomab Therapeutics NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for Chemomab Therapeutics's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chemomab Therapeutics NonCurrent Deferred Liabilities Chart

Chemomab Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Chemomab Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
CMMB
33GF Score
Chemomab Therapeutics Ltd CMMB
NonCurrent Deferred Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Liabilities of $0.00 Mil mean?
Chemomab Therapeutics (CMMB) has a NonCurrent Deferred Liabilities of $0.00 Mil as of Mar. 2026. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Chemomab Therapeutics and its competitors.
Is Chemomab Therapeutics' NonCurrent Deferred Liabilities too high?
Chemomab Therapeutics' current NonCurrent Deferred Liabilities is $0.00 Mil. Overall, Chemomab Therapeutics has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Chemomab Therapeutics' NonCurrent Deferred Liabilities compare to OSRH and TOVX?
Chemomab Therapeutics' NonCurrent Deferred Liabilities of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Biotechnology company?
A good NonCurrent Deferred Liabilities depends on the Biotechnology industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Chemomab Therapeutics and its competitors. Chemomab Therapeutics's current NonCurrent Deferred Liabilities is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chemomab Therapeutics stock overvalued right now?
Chemomab Therapeutics (CMMB) has a current NonCurrent Deferred Liabilities of $0.00 Mil. The current NonCurrent Deferred Liabilities is $0.00 Mil. Chemomab Therapeutics' overall GF Score™ is 33/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For Chemomab Therapeutics (CMMB), the current NonCurrent Deferred Liabilities is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Chemomab Therapeutics Business Description

Address 10 Habarzel Street, 10th Floor, Building C, Tel Aviv, ISR, 6158101
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.
33GF Score

Get the complete analysis for CMMB

NonCurrent Deferred Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.40
Price